Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, recently published its top ten 2007 predictions. The number one prediction for 2007 is that once Democrats gain control of the United States legislature in 2007, they will enact major reform that will dramatically alter the current prescription drug landscape. The published paper, which can be accessed at www.decisionresources.com entitled "Top Ten Pharma Predictions for 2007," finds that these reforms will include enabling the government to negotiate prices for Medicare, the elimination of authorized generics, and the introduction of the reimportation of drugs into the U.S.
"The level of success Democrats will achieve in enacting change will depend entirely on the alliances they build with the Bush administration, the Republicans, and the pharmaceutical industry," said Joe Walsh, vice president at Decision Resources, Inc. "If the Democrats attempt to simply push their agenda without building a consensus, many of their initiatives will likely face a veto from President Bush."
"Top Ten Pharma Predictions for 2007" also forecasts that: * AstraZeneca/AtheroGenics' AGI-1067 will receive approval for coronary heart disease and grow to blockbuster status * Genentech/Roche's Avastin will be indicated for a variety of new cancers * Sanofi-Aventis' Acomplia, a first-in-class cannabinoid receptor antagonist used to treat obesity, diabetes, hypertension, and dyslipidemia-will be reimbursed * Biosimilar Epogen will receive EU approval
For a copy of the entire Decision Resources' "Top Ten Pharma Predictions for 2007" article, please contact Chris Comfort at ccomfort@dresources.com or 781-296-2597 or visit www.decisionresources.com to download the published paper.
About Decision Resources
Decision Resources, Inc., (www.DecisionResources.com) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Christopher Comfort Decision Resources, Inc. 781-296-2597 ccomfort@dresources.com
SOURCE: Decision Resources, Inc.
CONTACT: Christopher Comfort of Decision Resources, Inc.,
+1-781-296-2597, or ccomfort@dresources.com
Web site: http://www.decisionresources.com/